Business Wire - December 6, 2007
"We are pleased to partner with Roche Diagnostics - a world leader in diagnostics - to leverage its distribution and marketing strengths to quickly get the anti-HIV drug monitoring products to market," said Johnny Valdez, president of ARK Diagnostics. "Roche will be immediately selling and distributing our products worldwide."
The Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) impacts 1.2 million people in the U.S. alone and more than 40,000 people become newly infected each year. The treatment for HIV infection consists of combination therapy of three or more drugs which work against HIV infection itself by slowing down the replication of HIV in the body. The potential world-wide market for HIV drug monitoring products is estimated at $100-150 million annually.
"This agreement is an example of our commitment and strategic relationship with ARK Diagnostics, Inc. and an important step in our efforts in improving the quality of health care for HIV-infected patients," said Oliver Strobel, director of business development at Roche Applied Science, a division of Roche Diagnostics.
ARK's products are immunoassay reagents for certain classes of anti-HIV drugs such as protease inhibitors and nonnucleoside reverse transcriptase inhibitors used to suppress viral replication. The immunoassay reagents are compatible with most automated clinical chemistry analyzers and measure a patient's blood level of anti-HIV drug, helping doctors to determine if adequate drug exposure has been achieved at a given dose.
"Monitoring tests for viral load and cell markers have contributed significantly to improving the lives of those infected with HIV; the added benefit of measuring drug level is thought to enhance therapy by assuring patients achieve the effective circulating concentration of drug with the dosage used," Valdez said. "We look forward to continuing to develop our TDM product portfolio to help those with HIV and other diseases who may benefit from continuous monitoring."
About ARK Diagnostics, Inc.
ARK is a scientific leader in pioneering the development of new in vitro diagnostic immunoassay reagents for therapeutic drug monitoring. This includes the development of innovative homogeneous immunoassay reagents for quantifying antiretrovirals used as part of highly active antiretroviral therapy (HAART) for the treatment of human immunodeficiency virus (HIV) type 1. Helping healthcare professionals to better monitor and manage treatment is an increasingly important challenge in modern healthcare. The company's TDM reagents are designed to enable individualized therapy and address unmet clinical needs. High-quality, convenient, and cost-effective reagents enable routine use of TDM in clinical practice and research settings. The company's innovative TDM reagents are designed to serve healthcare institutions, researchers, and clinical laboratories. Founded in 2003, ARK Diagnostics, Inc. is located in Sunnyvale, CA. Additional information about ARK is available at www.ark-tdm.com.
Contacts
ARK Diagnostics, Inc. | Ken C. Kasper, Ph.D, 408-747-0708 | Director Quality Assurance and Compliance | ken@ark-tdm.com
071206
BW071207
Copyright © 2007 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .